SCHEMBL25079645

SCHEMBL25079645

CC(C)(C)OC(=O)NCc1ccc(COc2cccc(N3CCC(=O)NC3=O)c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DDB1 Q16531 10/20 0.61
▸ CRBN Q96SW2 10/20 0.61
▸ HDAC1 Q13547 1/20 0.47
▸ BRD4 O60885 1/20 0.42
▸ CREBBP Q92793 1/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ GFER P55789 1/20 0.41
▸ HSD17B10 Q99714 1/20 0.41
▸ NAMPT P43490 1/20 0.41
▸ PLG P00747 1/20 0.40
▸ PSMB1 P20618 1/20 0.39
▸ PSMB8 P28062 1/20 0.39
▸ PSMB9 P28065 1/20 0.39
▸ PSMB5 P28074 1/20 0.39
▸ PSMB10 P40306 1/20 0.39
▸ PSMB2 P49721 1/20 0.39
▸ TNKS O95271 1/20 0.39
▸ PARP1 P09874 1/20 0.39
▸ TNKS2 Q9H2K2 1/20 0.39
▸ MEN1 O00255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23142739 0.82 DDB1 (0.62) DDB1CRBNHSD17B10
SCHEMBL30257675 0.79 DDB1 (0.64) DDB1CRBNHSD17B10MEN1KMT2A
SCHEMBL25079169 0.79 CRBN (0.56) DDB1CRBNHDAC1BRD4CREBBP
SCHEMBL25079638 0.79 DDB1 (0.72) DDB1CRBNHSD17B10MEN1KMT2A
SCHEMBL38654966 0.77 DDB1 (0.54) DDB1CRBNBRD4CREBBPL3MBTL1
SCHEMBL31393572 0.76 DDB1 (0.56) DDB1CRBNHDAC1BRD4CREBBP
SCHEMBL31040961 0.76 DDB1 (1.00) DDB1CRBNBRD4CREBBPL3MBTL1
SCHEMBL25079168 0.76 MAOB (0.55) HDAC1L3MBTL1
SCHEMBL17136480 0.75 HDAC1 (0.65) HDAC1L3MBTL1NAMPTMEN1KMT2A
SCHEMBL25079218 0.75 DDB1 (0.59) DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023023531-A1 ESTROGEN RECEPTOR DEGRADERS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS BIOTHERYX, INC. (US) 2023-02-23 — — WO disclosed
Send feedback